Physicians' awareness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer carcinomatosis Background: Recent trials have shown that cytoreductive surgery and heated intraperitoneal chemotherapy (S+HIPEC) for colorectal cancer carcinomatosis (CRC-C) leads to 5-year, disease-free survival rates of more than 30%. Since these data represent a substantial change in the management of CRC-C, the objectives of this study were to determine physicians' awareness of S+HIPEC for CRC-C and physician characteristics predictive of awareness of S+HIPEC for CRC-C.
C
olorectal cancer carcinomatosis (CRC-C) affects about 10% of all patients with colorectal cancer, and it is the second most common cause of death in these patients after metastatic liver disease. 1 Until recently, CRC-C was considered incurable, and cytoreductive surgery combined with hyperthermic intraperitoneal surgery (S+HIPEC) was reserved only for appendiceal tumours or pseudomyxoma. 2 However, in 2003 a randomized controlled trial (RCT) showed a significant improvement in median survival with S+HIPEC for CRC-C relative to best systemic chemotherapy (22.4 mo v. 12.6 mo, p = 0.032). This trial also showed that median survival was significantly better in patients with low-volume disease (> 29 mo v. 5.4 mo, p < 0.001) and in those who had a macroscopically complete cytoreduction (p < 0.001). After 8 years, the 5-year survival was 45% in patients who achieved a macroscopically complete cytoreduction. 3 Based on this RCT and 10 other phase II trials, an international consensus statement was published by the Society of Surgical Oncology (SSO) recommending the use of S+HIPEC for appropriately selected patients with CRC-C. 4 Despite this evidence supporting S+HIPEC for CRC-C, there has been little systematic investigation into physicians' awareness of S+HIPEC for CRC-C. This is important, since lack of physician awareness may result in eligible patients with CRC-C not being referred for S+HIPEC. 5, 6 Physician awareness is the first sequential step necessary for successful implementation of a new intervention into clinical practice. 7, 8 Therefore, the objectives of the present study were, first, to determine physicians' awareness of S+HIPEC for CRC-C and, second, to determine physician characteristics predictive of awareness of S+HIPEC for CRC-C.
METHODS
The research ethics board at our institution approved our study protocol. This study was a cross-sectional, mailed survey of general surgeons and medical oncologists in the province of Ontario, Canada. The population of Ontario is approximately 13 million, and health care is publicly funded by the government.
Eligible physicians (general surgeons, medical oncologists) were identified using the website of the province's medical licensing body, the College of Physicians and Surgeons of Ontario (CPSO). The CPSO website is publicly accessible, updated annually and contains the name, address and specialty of all licensed physicians in Ontario. We considered physicians to be eligible to participate if they were registered as active general surgeons or medical oncologists working as full-time staff members at any Ontario hospital.
We developed a 12-item questionnaire to obtain demographic information (5 items on a categorical scale) and to assess physicians' awareness of S+HIPEC and their perceived barriers to the use of this treatment for pseudomyxoma and CRC-C (7 items on a categorical scale). Since S+HIPEC has been an accepted treatment for pseudomyxoma for more than 10 years, we expected that physicians' awareness of S+HIPEC for pseudomyxoma would be greater than for CRC-C. Therefore, we used physicians' awareness of S+HIPEC for pseudomyxoma as the baseline to compare physicians' awareness of S+HIPEC for CRC-C.
The survey was pilot-tested among 5 health care professionals to ensure face validity and comprehension.
Data collection
We collected data using the Dillman method. 9 Study packages contained the survey; a personalized, signed cover letter; and a stamped and addressed return envelope. Six weeks after the initial mail-out, a second package was mailed to nonresponders. Six weeks after the second mailout, we contacted the remaining nonresponders by telephone as a final reminder to complete the survey.
Statistical analysis
Descriptive statistics are presented as percentages and frequencies; χ 2 tests of association were used to compare respondent characteristics and awareness of S+HIPEC for pseudomyxoma and CRC-C. We performed Fisher exact tests when more than 25% of the subgroups examined (cells) were populated by fewer than 5 respondents. Logistic regression was used to model the physicians' awareness of S+HIPEC for pseudomyxoma and CRC-C on physician characteristics. We conducted Hosmer-Lemeshow goodness of fit tests to verify the appropriateness of each model. All analyses were conducted using SAS software version 9.2
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RESULTS
We mailed the survey to 658 Ontario physicians (general surgeons, medical oncologists). Of these, 62 surveys were returned undelivered, and these physicians were not subsequently contacted with a follow-up telephone call. In all, 334 surveys were returned; of these, 214 were complete and 41 were ineligible (retirement [n = 7], not currently treating patients with pseudomyxoma and did not complete the 11 The response rate for general surgeons was significantly higher than for medical oncologists (47% general surgeons v. 32%, p = 0.007; Table 1 ). Compared with responders, nonresponders were similar with respect to sex (75% v. 81% were men, p = 0.08), but were significantly more likely to have been in practice for more than 20 years (44% v. 28%, p < 0.001) and be medical oncologists (24% v. 14%, p = 0.004).
The respondents' demographic characteristics are shown in Table 1 . Most respondents were men (75%), younger than 50 years (64%) and fellowship-trained (83%). There was a fairly even split between physicians who had been working for less than or more than 10 years and between those working in community and academic hospitals. Overall, medical oncologists were more likely than general surgeons to be women, practise in academic hospitals and be fellowship-trained.
The overall results of the survey showed that while 86% of the respondents were aware of S+HIPEC for pseudomyxoma, only 46% were aware of this treatment for CRC-C ( Table 2 ). General surgeons were significantly more likely to be aware of S+HIPEC for pseudomyxoma than medical oncologists (88% general surgeons v. 72% medical oncologists, p = 0.039). There was no significant difference in the level of awareness between general surgeons and medical oncologists (47% general surgeons v. 41%, p = 0.69) for S+HIPEC for CRC-C. On average the respondents indicated that they saw more than 10 patients with pseudomyxoma and/or CRC-C every year, and most respondents referred patients to another centre in the province. Eighty percent of the respondents indicated that they did not have a specialized treatment program for pseudomyxoma or CRC-C at their centre. Medical oncologists were significantly more likely than general surgeons to be unaware of a specialized treatment program at their centre (22.2% medical oncologists, v. 4.9% general surgeons, p = 0.010).
The respondents indicated that the main reason for not referring patients for treatment were, first, patient characteristics and comorbidities (47.3%) and, second, lack of awareness of existing treatment programs (20.4%). Medical oncologists were significantly more likely than general surgeons to indicate that they did not refer patients owing to lack of evidence for S-HIPEC (medical oncologists 22.7 v. general surgeons 5.5%, p = 0.014).
With respect to barriers to referring patients for treatment, 16% of respondents indicated that there were no barriers, whereas 18% indicated long waiting lists and 19% indicated no specialized physicians and/or centres as barriers. Twentytwo percent of respondents also indicated that patient preferences for treatment was a significant barrier to referral.
We performed multivariate logistic regression analysis to identify physician characteristics predictive of awareness of S+HIPEC for both pseudomyxoma and CRC-C (Table 3) . Of the independent variables selected (sex, years in practice, type of practice, specialty and existence of HIPEC program at respondent's centre), specialty and working in an academic hospital were predictive of physician awareness for S+HIPEC for pseudomyxoma, Overall, university-based physicians were 2.7 times (95% confidence interval [CI] 1.09-6.73) more likely to be aware of S+HIPEC than community-based physicians, and general surgeons were 3.65 times (95% CI 1.27-10.48) more likely to be aware of S+HIPEC than medical oncologists. There were no physician characteristics predictive of awareness of S+HIPEC for CRC-C.
DISCUSSION
Our study assessed physician awareness of S+HIPEC for CRC-C in the province of Ontario. While 86% of respondents were aware of S+HIPEC for pseudomyxoma, only 46% were aware of S+HIPEC for CRC-C. These findings suggest that physicians' awareness of S+HIPEC for CRC-C is low in the province of Ontario. Since lack of awareness may result in eligible patients with CRC-C not being referred for S+HIPEC, strategies to improve physician awareness are critical to ensure physician adoption of this treatment and appropriate referral of patients. Based on these survey results, educational strategies to improve CI = confidence interval; OR = odds ratio. *% of correlate. For example, 87.6% of male respondents are aware of S+HIPEC compared with 81.1% of female respondents; however, this difference is not statistically significant. †Program offering treatment could not be examined as a predictor in the model for pseudomyxoma, given that 100% of physicians with access to such centres reported knowledge of or recommending cytoreductive surgery and HIPEC.
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physician awareness about the effectiveness of S+HIPEC for CRC-C are necessary. Since the principles of adult learning include self-direction and emphasis on real life situations, strategies with the greatest chance of success include reinforcement, sequential activities and interaction among the participants and involve opinion leaders. 12 For this purpose, a series of Internet or webinar case presentations followed by review of the evidence and online discussion among physicians and opinion leaders may be an excellent format to improve awareness of S+HIPEC for CRC-C. 12 At the time of the survey, while Nova Scotia (Halifax), Quebec (Montréal) and Alberta (Calgary and Edmonton) had specialized centres for HIPEC, there were no specialized centres offering HIPEC in Ontario. Therefore, it was not surprising that only a small proportion of the respondents (i.e., 13.3%) indicated that there was a specialized treatment program for these patients at their centre. Despite this, only 20% of respondents indicated lack of awareness of existing treatment programs and only 19% indicated lack of a specialist or specialty centre as a barrier to referral of these patients. Furthermore, regression analysis did not show that current awareness of an existing treatment program at the respondent's own centre was predictive of physician awareness of S+HIPEC as a treatment option for CRC-C. This may be because, at the time of the survey, none of these treatment programs was routinely offering S+HIPEC for CRC-C, but it is also likely because of our small sample size and inadequate power to detect important differences.
Interestingly, almost 50% of the respondents indicated that the main reason for not referring patients for treatment were patient characteristics and comorbidities. These findings were important to our centre, since it was designated as the provincial centre for S+HIPEC for pseudomyxoma and CRC-C in February 2011 after completion of our survey. Since we found both a lack of awareness about existing programs and a lack of awareness of appropriate selection of patients, our group developed a referral checklist for referring physicians that provides an explicit list of indications and contraindications for S+HIPEC for pseudomyxoma and CRC-C to assist physicians with the referral process (Box 1).
It is interesting that medical oncologists were less likely than general surgeons to consider S+HIPEC as a treatment option for pseudomyxoma and more likely to indicate there was a lack of evidence to support the use of this treatment. With respect to CRC-C, the overall awareness of S+HIPEC was much lower, and there were no differences between general surgeons and medical oncologists. Therefore, educational strategies that target a multidisciplinary audience, including medical oncologists, need to be strongly considered. Furthermore, since the management of these patients is complex, strategies to improve com munication among general surgeons, medical oncologists and family physicians will be critical to improve awareness and adoption of S+HIPEC for CRC-C.
Finally, the respondents indicated that patient preferences were one of the main barriers to referral of CRC-C patients for S+HIPEC. This is certainly an issue that needs to be explored in future studies, since there has been little systematic investigation of patients' preferences for S+HIPEC or the reasons for why they would choose or not choose S+HIPEC. In this regard, development of decisionsupport interventions or a decision aid for both physicians and patients is warranted and has been shown to be an effective strategy to assist treatment decision making and improve patient outcomes in other cancer settings.
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Limitations
The main limitation of this study was the low overall response rate of 44%. Although there was no difference in sex between responders and nonresponders, fewer physicians in practice for more than 20 years and fewer medical oncologists responded to the survey, which may have led to important response bias, thus limiting the validity and generalizability of our results. Furthermore, these data were based on self-report rather than observed behaviour and therefore may not accurately reflect what physicians may actually recommend in their clinical practices. Finally, although we included both general surgeons and medical oncologists in the survey, we did not include primary care physicians, and this information would have been useful to assess their level of awareness with S+HIPEC and plan targeted educational interventions in this physician population.
CONCLUSION
Physician awareness of S+HIPEC for CRC-C in Ontario is low. Our results suggest that educational strategies to 
